Intimate associations between the endogenous opiate systems and the growth hormone-releasing hormone system in the human hypothalamus

Olsen, J.; Peroski, M.; Kiczek, M.; Grignol, George; Merchenthaler, Istvån; Dudás, Bertalan

doi:10.1016/j.neuroscience.2013.11.011

Cited by 7 publications

(1 citation statement)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistently, a reduction in the number of cells in the proliferation zone of the growth plate (and the growth plate width) under the influence of morphine was demonstrated in young rats (Ezzatabadipour et al 2011). Also, a restriction of fetal growth often occurs during pregnancy in opioid-dependent women, although numerous studies have demonstrated the stimulatory effect of opioids on the secretion of growth hormone (Olsen et al 2014). Neither buprenorphine, a partial μ receptor agonist and κ receptor antagonist, nor naloxone, an opioid receptor antagonist, affected the longitudinal bone growth.…”

Section: Discussionmentioning

confidence: 99%

Opioid receptor agonists may favorably affect bone mechanical properties in rats with estrogen deficiency-induced osteoporosis

Janas

Folwarczna

2016

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

The results of epidemiological, clinical, and in vivo and in vitro experimental studies on the effect of opioid analgesics on bone are inconsistent. The aim of the present study was to investigate the effect of morphine (an agonist of opioid receptors), buprenorphine (a partial μ opioid receptor agonist and κ opioid receptor antagonist), and naloxone (an antagonist of opioid receptors) on the skeletal system of female rats in vivo. The experiments were carried out on 3-month-old Wistar rats, divided into two groups: nonovariectomized (intact; NOVX) rats and ovariectomized (OVX) rats. The bilateral ovariectomy was performed 7 days before the start of drug administration. Morphine hydrochloride (20 mg/kg/day s.c.), buprenorphine (0.05 mg/kg/day s.c.), or naloxone hydrochloride dihydrate (2 mg/kg/day s.c.) were administered for 4 weeks to NOVX and OVX rats. In OVX rats, the use of morphine and buprenorphine counteracted the development of osteoporotic changes in the skeletal system induced by estrogen deficiency. Morphine and buprenorphine beneficially affected also the skeletal system of NOVX rats, but the effects were much weaker than those in OVX rats. Naloxone generally did not affect the rat skeletal system. The results confirmed the role of opioid receptors in the regulation of bone remodeling processes and demonstrated, in experimental conditions, that the use of opioid analgesics at moderate doses may exert beneficial effects on the skeletal system, especially in estrogen deficiency.

show abstract

Section: Discussionmentioning

confidence: 99%